Mereo Historical Income Statement
| MREO Stock | USD 3.61 0.05 1.40% |
Historical analysis of Mereo BioPharma income statement accounts such as Selling General Administrative of 16.3 M can show how well Mereo BioPharma Group performed in making a profits. Evaluating Mereo BioPharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Mereo BioPharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Mereo BioPharma Group latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Mereo BioPharma Group is a good buy for the upcoming year.
Mereo |
About Mereo Income Statement Analysis
Mereo BioPharma Group Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Mereo BioPharma shareholders. The income statement also shows Mereo investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Mereo BioPharma Income Statement Chart
Add Fundamental
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Mereo BioPharma Group financial statement analysis. It represents the amount of money remaining after all of Mereo BioPharma Group operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Mereo BioPharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Mereo BioPharma Group current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. At this time, Mereo BioPharma's Interest Income is very stable compared to the past year. As of the 1st of December 2024, Interest Expense is likely to grow to about 2.9 M, while Tax Provision is likely to drop (558.6 K).
Mereo BioPharma income statement Correlations
Click cells to compare fundamentals
Mereo BioPharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Mereo BioPharma income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Tax Provision | (6.3M) | (2.8M) | 1.5M | (1.9M) | (532K) | (558.6K) | |
| Interest Income | 183K | 5K | 1K | 696K | 2.1M | 2.2M | |
| Interest Expense | 3.5M | 6.4M | 4.0M | 3.4M | 2.9M | 2.9M | |
| Selling General Administrative | 15.9M | 21.2M | 15.9M | 19.5M | 18.4M | 16.3M | |
| Total Revenue | (122K) | 393K | 36.5M | 1.5M | 10M | 5.5M | |
| Gross Profit | (23.7M) | (16.0M) | 18.6M | 571K | 7.4M | 7.8M | |
| Other Operating Expenses | 39.5M | 37.6M | 57.4M | 43.6M | 38.4M | 40.7M | |
| Operating Income | (39.5M) | (37.6M) | (20.9M) | (43.6M) | (28.4M) | (29.8M) | |
| Net Income From Continuing Ops | (34.8M) | (163.6M) | 12.7M | (34.2M) | (29.5M) | (30.9M) | |
| Ebit | (39.5M) | (37.6M) | (5.9M) | (43.6M) | (27.1M) | (28.5M) | |
| Research Development | 23.6M | 16.3M | 23.6M | 25.0M | 17.4M | 16.5M | |
| Cost Of Revenue | 23.6M | 16.3M | 17.9M | 936K | 2.6M | 2.4M | |
| Total Operating Expenses | 15.9M | 21.2M | 39.5M | 44.5M | 35.8M | 63.1M | |
| Income Before Tax | (41.1M) | (166.5M) | 14.2M | (36.1M) | (30.0M) | (31.5M) | |
| Total Other Income Expense Net | (1.6M) | (129.3M) | 40.2M | 7.5M | (1.6M) | (1.7M) | |
| Net Income Applicable To Common Shares | (34.8M) | (163.6M) | 12.7M | (34.2M) | (30.8M) | (32.3M) | |
| Net Income | (34.8M) | (163.6M) | 12.7M | (34.2M) | (29.5M) | (30.9M) | |
| Income Tax Expense | (6.3M) | (2.8M) | 1.5M | (1.9M) | (532K) | (558.6K) | |
| Net Interest Income | (3.6M) | (6.3M) | (4.0M) | (2.7M) | (750K) | (787.5K) | |
| Depreciation And Amortization | 2.0M | 44K | 866.5K | 1.5M | 1.1M | 761.7K | |
| Ebitda | (37.6M) | (37.5M) | (5.0M) | (42.1M) | (26.1M) | (27.4M) | |
| Reconciled Depreciation | 1.6M | 1.6M | 642K | 727K | 1.1M | 892.6K |
Pair Trading with Mereo BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against Mereo Stock
| 0.67 | VTRS | Viatris | PairCorr |
| 0.67 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.56 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.51 | GILD | Gilead Sciences | PairCorr |
| 0.47 | WAT | Waters | PairCorr |
The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.
The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share 0.007 | Return On Assets (0.24) | Return On Equity (0.48) |
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.